Paul J Collini

Paul J Collini i

University of Sheffield - Sheffield / United Kingdom
Medical and Health Sciences / Infectious Diseases
AD Scientific Index ID: 1282744
Sheffield University
person_outline Paul J Collini's MOST POPULAR ARTICLES
1-) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialRECOVERY Collaborative GroupLancet (London, England) 397 (10285), 1637, 20211485*2021
2-) SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responsesW Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ...Cell 185 (3), 467-484. e15, 20227192022
3-) Mapping the human genetic architecture of COVID-19Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...Nature 600 (7889), 472-477, 20216592021
4-) D614G spike mutation increases SARS CoV-2 susceptibility to neutralizationD Weissman, MG Alameh, T de Silva, P Collini, H Hornsby, R Brown, ...Cell host & microbe 29 (1), 23-31. e4, 20213752021
5-) Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre …CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ...The Lancet Microbe 2 (8), e354-e365, 20213232021